MedTrace Logo

Chronic Intervention With Sulforaphane-Smart® in Overweight and Obese Adults

NCT06964659 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-05-09

No results posted yet for this study

Summary

The Sulforaphane-Smart® formula is a pill, patented by the company INGREDALIA, prepared with broccoli by-products which have been concentrated and enriched in glucosinolates/isothiocyanates (GLS/ITCs).

The goal of this intervention study is to evaluate if the chronic consumption of GSL/ITC (Sulforaphane Smart® formula) could modulate the biomarkers related to chronic inflammation, oxidative stress and gut microbiota in overweight and obese volunteers.

In order to reach this goal, the volunteers will take daily the Sulforaphane Smart® formula during 12 weeks (total of 84 days). Anthropometric measurements will be taken and biological samples of blood, urine and feces will be collected at the beginning of the intervention (initial time), after six weeks of the intervention (Time 6 weeks) and at the end of the intervention (Time 12 weeks).

Conditions

  • Obesity and Overweight

Interventions

DIETARY_SUPPLEMENT

Sulforaphan-Smart® formula

Volunteers will intake a daily dose of Sulforaphan-Smart® pill for 12 weeks (84 days)

OTHER

Control (placebo) group

Volunteers will intake a daily dose of placebo pill for 12 weeks (84 days)

Sponsors & Collaborators

  • Ingredalia Company

    collaborator UNKNOWN

  • Spanish National Research Council (CEBAS-CSIC)

    collaborator UNKNOWN

  • Mª Jesús Periago

    lead OTHER

Principal Investigators

  • Rocío González Barrio, PhD · Universidad de Murcia

  • María Jesús Periago Castón, PhD · Universidad de Murcia

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06964659 on ClinicalTrials.gov